An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus (TRACK)
An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ibaragi
-
Naka-city, Ibaragi, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements.
- Participants who are able to sign and date the informed consent form and information sheet prior to the start of study procedures.
- Participants diagnosed with type 2 diabetes mellitus.
- Participants with a glycated hemoglobin (HbA1c) [National Glycohemoglobin Standardization Program (NGSP value)] value ≥ 6.5% and < 8.5% at the start of the observation period (Day -2).
- Participants who experience a ≤ ±1.0% change in HbA1c (NGSP value) at the start of the observation period (Day -2) as compared with an HbA1c value obtained during the preceding 6 weeks.
- Participants receiving stable dietetic therapy and exercise therapy (if performed) for ≥ 4 weeks before the start of the observation period.
- Participants, who in the opinion of the principal investigator or the investigator, does not have to change (including discontinuation or interruption) 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors or add new HMG-CoA reductase inhibitors during treatment period.
- Men or women aged 20 years or older at the time of informed consent.
Exclusion Criteria:
- Participants who received anti-diabetic medications within 4 weeks prior to the start of the observation period.
- Participants who have changed (including discontinuation or interruption) HMG-CoA reductase inhibitors or received new HMG-CoA reductase inhibitors ≤ 4 weeks before the start of the observation period.
- Participants with clinically evident hepatic dysfunction (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5-fold the upper limit of normal at the start of the observation period [Day -2]).
- Participants with moderate renal dysfunction, severe renal dysfunction or renal failure (e.g., creatinine clearance < 50 mL/min or serum creatinine > 1.4 mg/dL in men or > 1.2 mg/dL in women [equivalent to the creatinine clearance for persons aged 60 years with a body weight of 65 kg] at the start of the observation period [Day -2]).
- Participants with severe heart disease, cerebrovascular disorder, or severe pancreatic, hematologic or other diseases.
- Participants with a history of gastric or small intestinal resection.
- Participants with proliferative diabetic retinopathy.
- Participants warranting insulin therapy for glycemic control (e.g., participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, perioperative participants, or serious trauma).
- Participants with a history of hypersensitivity or allergy to DPP-4 inhibitors.
- Participants who experience an allergic reaction to metal during CGM at the start of the observation period (Day -2).
- Participants with any malignant tumors.
- Habitual drinkers whose average daily alcohol consumption is > 100 mL.
- Participants who have any contraindications for the study drug or are taking any contraindicated concomitant drugs listed in the package insert.
- Participants anticipated to require any prohibited concomitant medications during the study period.
- Participants who are day and night lifestyle reversal.
- Participants participating in any other clinical studies at the time of informed consent for this study.
- Pregnant women, nursing mothers, women who are possible pregnant, or women who plan to become pregnant.
- Other participants who are considered inappropriate for participation in this study in the opinion of the principal investigator or investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Trelagliptin 100 mg group
Trelagliptin 100 mg once weekly taken orally before breakfast
|
Trelagliptin 100 mg tablet
|
|
Experimental: Alogliptin 25 mg group
Alogliptin 25 mg once daily taken orally before breakfast
|
Alogliptin 25 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values
Time Frame: Baseline, up to 28 days
|
Changes in the SD of 24-hour blood glucose values (mg/dL) for each 7-day period between Week 3 and Week 4 (between Day 2 on Week 3 [Day 22] and Day 8 on Week 3 [Day 28]) of the treatment period, calculated from the value at the start of the observation period.
|
Baseline, up to 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (180 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose when specific blood glucose levels (180 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (110 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose when specific blood glucose levels (110 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (140 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose when specific blood glucose levels (140 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (160 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose when specific blood glucose levels (160 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 140 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 140 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 160 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 160 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 180 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 180 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Time During Periods When Blood Glucose Levels Reached 140 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in cumulative time during periods when blood glucose levels reached 140 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Time During Periods When Blood Glucose Levels Reached 160 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in cumulative time during periods when blood glucose levels reached 160 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Time During Periods When Blood Glucose Levels Reached 180 mg/dL (Hyperglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in cumulative time during periods when blood glucose levels reached 180 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels is Less Than 70 mg/dL (Hypoglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose during periods when blood glucose levels was less than 70 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Peak Postprandial Glucose Levels During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in peak postprandial glucose levels during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Maximum Variation of Blood Glucose Levels Between Before and After Breakfast, Lunch, and Evening Meal
Time Frame: Baseline, up to 28 days
|
Change from baseline in maximum variation of glucose levels between before and after breakfast, lunch and evening meal at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Mean Amplitude Glycemic Excursions (MAGE)
Time Frame: Baseline, up to 28 days
|
Change from baseline in MAGE at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Mean 24-hour Blood Glucose Levels
Time Frame: Baseline, up to 28 days
|
Change from baseline in mean 24-hour blood glucose levels at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Mean Daytime Blood Glucose Levels
Time Frame: Baseline, up to 28 days
|
Change from baseline in mean daytime blood glucose levels at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in Mean Nocturnal Blood Glucose Levels
Time Frame: Baseline, up to 28 days
|
Change from baseline in mean nocturnal blood glucose levels at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose levels at each time points was calculated.
|
Baseline, up to 28 days
|
|
Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 110 mg/dL (Hypoglycemia)
Time Frame: Baseline, up to 28 days
|
Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 110 mg/dL at each time points was calculated.
|
Baseline, up to 28 days
|
|
Standard Deviation (SD) of 24-hour Blood Glucose Values
Time Frame: Baseline, up to 28 days
|
Baseline, up to 28 days
|
|
|
Changes From Baseline in the SD of Daytime Blood Glucose Values
Time Frame: Baseline, up to 28 days
|
Change from baseline in SD of daytime blood glucose values at each time points was calculated.
|
Baseline, up to 28 days
|
|
Changes From Baseline in the SD of Nocturnal Blood Glucose Values
Time Frame: Baseline, up to 28 days
|
Change from baseline in SD of nocturnal blood glucose values at each time points was calculated.
|
Baseline, up to 28 days
|
|
Number of Participants Reporting One or More Treatment-emergent Adverse Events
Time Frame: Up to 29 days
|
Up to 29 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Director, Takeda
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Alogliptin
Other Study ID Numbers
Other Study ID Numbers
- Trelagliptin-4001
- U1111-1182-4062 (Other Identifier: UTN)
- JapicCTI-163250 (Registry Identifier: JapicCTI)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.